Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lifitegrast

FDA-approved product (solution/drops, ophthalmic), marketed as Lifitegrast, Xiidra.

Registered studies
39
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lifitegrast
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Dry eye syndrome
  • Eye disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other ophthalmologicals
FDA pharmacologic class
Lymphocyte Function-Associated Antigen-1 Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lifitegrast in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lifitegrast with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy

    NCT07560735 · start 2026-04

    Registered record
    Registry ID
    NCT07560735
    Conditions
    Dry Eye
    Interventions
    Lifitegrast Ophthalmic Solution 5.0% (Xiidra)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2027-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionLifitegrast Ophthalmic Solution 5.0% (Xiidra)
    PhasePhase 4
    Registry statusNot yet recruiting

  • This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye

    NCT07490535 · start 2026-03

    Registered record
    Registry ID
    NCT07490535
    Conditions
    Ocular Surface Disease; Dry Eye Syndrome (DES)
    Interventions
    (Xiidra®) Lifitegrast Ophthalmic Solution 5.0%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2026-11
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Surface Disease; Dry Eye Syndrome (DES)
    Intervention(Xiidra®) Lifitegrast Ophthalmic Solution 5.0%
    PhasePhase 4
    Registry statusNot yet recruiting

  • Switching From Xiidra to TRYPTYR

    NCT07267481 · start 2025-12-15

    Registered record
    Registry ID
    NCT07267481
    Conditions
    Dry Eye; Dry Eyes Chronic; Dry Eye Syndromes; Eye Diseases
    Interventions
    acoltremon 0.003%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-12-15
    Completion
    2026-05-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye; Dry Eyes Chronic; Dry Eye Syndromes; Eye Diseases
    Interventionacoltremon 0.003%
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

    NCT07111013 · start 2025-12

    Registered record
    Registry ID
    NCT07111013
    Conditions
    Dry Eye Disease
    Interventions
    Lifitegrast/perfluorohexyloctane (PFHO)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2025-12
    Completion
    2027-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease
    InterventionLifitegrast/perfluorohexyloctane (PFHO)
    PhasePhase 3
    Registry statusWithdrawn

  • A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

    NCT07128628 · start 2025-10-24

    Registered record
    Registry ID
    NCT07128628
    Conditions
    Dry Eye Disease
    Interventions
    Lifitegrast/Perfluorohexyloctane Fixed Dose Combination; Lifitegrast; Perfluorohexyloctane; Vehicle; Vehicle; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-10-24
    Completion
    2026-05-28
    Enrolment
    443

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease
    InterventionLifitegrast/Perfluorohexyloctane Fixed Dose Combination; Lifitegrast; Perfluorohexyloctane; Vehicle +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

    NCT07025811 · start 2025-07-09

    Registered record
    Registry ID
    NCT07025811
    Conditions
    Dry Eye Disease
    Interventions
    Vevye®; Xiidra®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-07-09
    Completion
    2026-07-16
    Enrolment
    378

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease
    InterventionVevye®; Xiidra®
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024

    NCT06624384 · start 2024-10-30

    Registered record
    Registry ID
    NCT06624384
    Conditions
    Ocular Surface Symptom; Ocular Surface Disease; Eye Pain; Eye Inflammation
    Interventions
    Group 1 drug; Group 2: Drug and placebo; Group 3: Drug and palcebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2024-10-30
    Completion
    2024-12-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Surface Symptom; Ocular Surface Disease; Eye Pain; Eye Inflammation
    InterventionGroup 1 drug; Group 2: Drug and placebo; Group 3: Drug and palcebo
    PhasePhase 1
    Registry statusNot yet recruiting

  • Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease

    NCT06879782 · start 2024-03-28

    Registered record
    Registry ID
    NCT06879782
    Conditions
    Dry Eye Disease (DED)
    Interventions
    Drug placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-03-28
    Completion
    2026-09-28
    Enrolment
    820

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease (DED)
    InterventionDrug placebo
    PhasePhase 3
    Registry statusRecruiting

  • Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease

    NCT05857748 · start 2023-07-31

    Registered record
    Registry ID
    NCT05857748
    Conditions
    Dry Eye Disease
    Interventions
    lifitegrast
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2023-07-31
    Completion
    2024-12-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease
    Interventionlifitegrast
    PhaseNot recorded
    Registry statusWithdrawn

  • Lifitegrast Eye Drops in Healthy Subjects：Phase I Study

    NCT07040826 · start 2022-12-06

    Registered record
    Registry ID
    NCT07040826
    Conditions
    Dry Eye Syndromes
    Interventions
    Xiidra; Lifitegrast
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-12-06
    Completion
    2023-04-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes
    InterventionXiidra; Lifitegrast
    PhasePhase 1
    Registry statusCompleted

  • The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

    NCT04792580 · start 2022-10-22

    Registered record
    Registry ID
    NCT04792580
    Conditions
    Graft-versus-host-disease; Ocular Graft-versus-host Disease
    Interventions
    Lifitegrast 5% Ophthalmic Solution; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2022-10-22
    Completion
    2024-04-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft-versus-host-disease; Ocular Graft-versus-host Disease
    InterventionLifitegrast 5% Ophthalmic Solution; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

    NCT05505292 · start 2022-09-22

    Registered record
    Registry ID
    NCT05505292
    Conditions
    Dry Eye
    Interventions
    Lifitegrast 5% Ophthalmic Solution; Lifitegrast Ophthalmic Solution Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-09-22
    Completion
    2023-05-15
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionLifitegrast 5% Ophthalmic Solution; Lifitegrast Ophthalmic Solution Vehicle
    PhasePhase 4
    Registry statusCompleted

  • An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

    NCT05102409 · start 2021-09-09

    Registered record
    Registry ID
    NCT05102409
    Conditions
    Dry Eye
    Interventions
    Reproxalap Ophthalmic Solution (0.25%); Xiidra® (5% lifitegrast ophthalmic solution)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-09
    Completion
    2021-10-25
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionReproxalap Ophthalmic Solution (0.25%); Xiidra® (5% lifitegrast ophthalmic solution)
    PhasePhase 2
    Registry statusCompleted

  • The Effect of Xiidra on Comfort and Dryness in Symptomatic Contact Lens Wearers

    NCT04297618 · start 2021-07-07

    Registered record
    Registry ID
    NCT04297618
    Conditions
    Dry Eye
    Interventions
    Xiidra
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-07-07
    Completion
    2024-04-18
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionXiidra
    PhasePhase 4
    Registry statusCompleted

  • Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

    NCT04120987 · start 2021-05-31

    Registered record
    Registry ID
    NCT04120987
    Conditions
    Dry Eye
    Interventions
    Lifitegrast 5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-05-31
    Completion
    2022-06-25
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionLifitegrast 5% Ophthalmic Solution
    PhasePhase 4
    Registry statusWithdrawn